Which statement regarding Bedaquiline (Bdq) is NOT true?

Bedaquiline is an antibiotic specifically indicated for the treatment of multidrug-resistant tuberculosis (MDR-TB). Understanding its classification and recommendations for use is crucial in ensuring effective treatment while minimizing risks.

The assertion that Bedaquiline is categorized as a Group B drug along with Clofazimine (Cfz) and Cycloserine (Cs) is not accurate. In pharmacological categories, Bedaquiline is generally classified differently, and it does not share the same category as Clofazimine and Cycloserine, which may have more established guidelines.

This classification is important as it reflects the drug's safety profile, potential interactions, and treatment protocols. The incorrect classification can lead to misunderstandings about its proper use and the necessary precautions that should be taken.

In contrast to this incorrect statement, Bedaquiline's use may require informed consent when prescribed off-label, and it is indeed advised not to be substituted with other drugs, even in cases of severe toxicity, without expert consultation. Hence, the statement regarding its categorization is not true, making it the correct response.